

## **CHANGE IN NUMBER OF SHARES AND VOTES IN MENDUS AB (PUBL)**

**As previously announced, Mendus AB (publ) ("Mendus") has, pursuant to the authorizations granted by the shareholders at the Annual General Meeting on May 6, 2025, issued a total of 1,725,000 Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares as well as to preserve liquidity. All Class C shares have been converted into ordinary shares.**

As a result thereof, the number of shares and votes in Mendus has changed. The issues of shares have resulted in an increase in the number of ordinary shares from 50,359,578 ordinary shares to 52,084,578 ordinary shares.

As of June 30, 2025, the last trading day of the month, there was a total of 52,084,578 ordinary shares and votes in Mendus.

### **For more information, please contact:**

Erik Manting

Chief Executive Officer

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

### **About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>

*This information is information that Mendus AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-06-30 08:00 CEST.*